Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/j.1479-828X.2009.01091.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Neuropathy with anti-myelin-associated glycoprotein antibodies: update on diagnosis, pathophysiology and management.
J Neurol Neurosurg Psychiatry
December 2024
Aston Medical School, Aston University, Birmingham, UK
Antimyelin-associated glycoprotein (MAG) neuropathy is a rare autoimmune demyelinating peripheral neuropathy caused by IgM autoantibodies targeting MAG. The typical presentation is that of a slowly progressive, distal, length-dependent, predominantly sensory, sometimes ataxic neuropathy, frequently accompanied by upper limb tremor. Distal motor weakness may subsequently occur.
View Article and Find Full Text PDFBackground: Though Aspirin and intravenous immunoglobulin (IVIG) remain the standard treatments for Kawasaki Disease (KD) to minimize coronary artery damage, the duration and dosage of aspirin are inconsistent across hospitals. However, the lack of multi-center randomized trials prevents definitive answers to the impact of high-dose aspirin.
Methods: This clinical trial was structured as a prospective, evaluator-blinded, multi-center randomized controlled trial with two parallel arms, aiming to assess the effectiveness of IVIG as a standalone primary therapy of KD in comparison to the combination of IVIG with high-dose aspirin therapy.
A Prospective Observational Study of Autoimmune Encephalitis in Northwestern India.
J Assoc Physicians India
September 2023
Consultant Neurologist, Amit Neuro Brain and Spine Care, Sikar, Rajasthan, India.
Objectives: Autoimmune encephalitis (AIE) is a group of rare, increasingly recognized, potentially reversible, noninfectious causes of unexplained encephalitis. It affects any age-group and has a plethora of clinical presentations, the most common being the neuropsychiatric manifestation. The diagnosis of this entity at the right time and proper treatment with immunotherapy can save many lives.
View Article and Find Full Text PDFPhysician awareness and understanding of chronic inflammatory demyelinating polyradiculoneuropathy in Japan: a web-based study.
BMJ Open
March 2024
Japan Medical Office, Takeda Pharmaceutical Company Limited, Tokyo, Japan.
Objectives: To investigate potential knowledge gaps between neurologists and non-specialists and identify challenges in the current management of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), with a focus on 'early diagnosis' and 'appropriate treatment' for CIDP.
Design: A non-interventional, cross-sectional, web-based quantitative survey of physicians working in healthcare clinics or hospitals in Japan.
Setting: Participants were recruited from the Nikkei Business Publications panel from 18 August to 14 September 2022.
Symptom and Treatment Satisfaction in Members of the US and Canadian GBS/CIDP Foundations with a Diagnosis of Chronic Inflammatory Demyelinating Polyneuropathy.
Adv Ther
December 2023
Toronto General Hospital, Ellen and Martin Prosserman Centre for Neuromuscular Disease, 200 Elizabeth Street 5ECW-334, Toronto, ON, M5G2C4, Canada.
Introduction: Current guidelines for defining good outcomes in patients with chronic inflammatory demyelinating polyneuropathy (CIDP) are predominately defined by experts. At present, we do not have a patient-anchored definition of what constitutes a "good" outcome. Our study aimed to assess the symptom burden of people living with CIDP, as well as satisfaction with treatments and clinical outcomes.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!